vs

Side-by-side financial comparison of Assertio Holdings, Inc. (ASRT) and Rocky Mountain Chocolate Factory, Inc. (RMCF). Click either name above to swap in a different company.

Assertio Holdings, Inc. is the larger business by last-quarter revenue ($13.5M vs $7.5M, roughly 1.8× Rocky Mountain Chocolate Factory, Inc.). On growth, Rocky Mountain Chocolate Factory, Inc. posted the faster year-over-year revenue change (-4.4% vs -57.9%). Over the past eight quarters, Rocky Mountain Chocolate Factory, Inc.'s revenue compounded faster (1.9% CAGR vs -35.4%).

Assertio Therapeutics, Inc. is an American specialty pharmaceutical company. It mainly markets products for treatment in neurology, pain and diseases of the central nervous system. Depomed was founded in 1995 and is headquartered in Newark, California. It is a publicly traded company on NASDAQ, with several products approved by the United States Food and Drug Administration (FDA). On August 15, 2018, the company announced its name change from Depomed, Inc., to Assertio Therapeutics, Inc. As o...

Rocky Mountain Chocolate, formerly Rocky Mountain Chocolate Factory, Inc., is an international franchiser, confectionery manufacturer and retail operator in the United States, with outlets in Panama and the Philippines. The company is based in the town of Durango, Colorado, United States of America.

ASRT vs RMCF — Head-to-Head

Bigger by revenue
ASRT
ASRT
1.8× larger
ASRT
$13.5M
$7.5M
RMCF
Growing faster (revenue YoY)
RMCF
RMCF
+53.5% gap
RMCF
-4.4%
-57.9%
ASRT
Faster 2-yr revenue CAGR
RMCF
RMCF
Annualised
RMCF
1.9%
-35.4%
ASRT

Income Statement — Q4 FY2025 vs Q3 FY2026

Metric
ASRT
ASRT
RMCF
RMCF
Revenue
$13.5M
$7.5M
Net Profit
$-155.0K
Gross Margin
34.0%
Operating Margin
-86.7%
1.1%
Net Margin
-2.1%
Revenue YoY
-57.9%
-4.4%
Net Profit YoY
81.7%
EPS (diluted)
$-4.54
$-0.02

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
ASRT
ASRT
RMCF
RMCF
Q4 25
$13.5M
$7.5M
Q3 25
$49.5M
$6.8M
Q2 25
$29.2M
$6.4M
Q1 25
$26.5M
$8.9M
Q4 24
$32.2M
$7.9M
Q3 24
$29.2M
$6.4M
Q2 24
$31.1M
$6.4M
Q1 24
$32.4M
$7.3M
Net Profit
ASRT
ASRT
RMCF
RMCF
Q4 25
$-155.0K
Q3 25
$11.4M
$-662.0K
Q2 25
$-16.4M
$-324.0K
Q1 25
$-13.5M
$-2.9M
Q4 24
$-847.0K
Q3 24
$-2.9M
$-722.0K
Q2 24
$-3.7M
$-1.7M
Q1 24
$-4.5M
$-1.6M
Gross Margin
ASRT
ASRT
RMCF
RMCF
Q4 25
34.0%
Q3 25
23.6%
Q2 25
31.1%
Q1 25
10.8%
Q4 24
23.4%
Q3 24
31.8%
Q2 24
12.8%
Q1 24
24.3%
Operating Margin
ASRT
ASRT
RMCF
RMCF
Q4 25
-86.7%
1.1%
Q3 25
23.2%
-7.0%
Q2 25
-27.5%
-2.3%
Q1 25
-50.0%
-30.3%
Q4 24
-41.9%
-8.9%
Q3 24
-10.4%
-14.3%
Q2 24
-11.6%
-25.4%
Q1 24
-13.4%
-21.7%
Net Margin
ASRT
ASRT
RMCF
RMCF
Q4 25
-2.1%
Q3 25
23.1%
-9.7%
Q2 25
-56.0%
-5.1%
Q1 25
-51.1%
-32.5%
Q4 24
-10.7%
Q3 24
-10.0%
-11.3%
Q2 24
-11.8%
-25.9%
Q1 24
-13.9%
-21.9%
EPS (diluted)
ASRT
ASRT
RMCF
RMCF
Q4 25
$-4.54
$-0.02
Q3 25
$0.11
$-0.09
Q2 25
$-0.17
$-0.04
Q1 25
$-0.14
$-0.38
Q4 24
$-3.28
$-0.11
Q3 24
$-0.03
$-0.11
Q2 24
$-0.04
$-0.26
Q1 24
$-0.05
$-0.25

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
ASRT
ASRT
RMCF
RMCF
Cash + ST InvestmentsLiquidity on hand
$63.4M
$641.0K
Total DebtLower is stronger
Stockholders' EquityBook value
$94.0M
$6.0M
Total Assets
$267.0M
$20.7M
Debt / EquityLower = less leverage

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
ASRT
ASRT
RMCF
RMCF
Q4 25
$63.4M
$641.0K
Q3 25
$93.4M
$2.0M
Q2 25
$98.2M
$893.0K
Q1 25
$87.3M
$720.0K
Q4 24
$100.1M
$1.1M
Q3 24
$88.6M
$973.0K
Q2 24
$88.4M
$637.0K
Q1 24
$80.7M
$2.1M
Total Debt
ASRT
ASRT
RMCF
RMCF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
$38.6M
Stockholders' Equity
ASRT
ASRT
RMCF
RMCF
Q4 25
$94.0M
$6.0M
Q3 25
$105.8M
$6.1M
Q2 25
$93.3M
$6.7M
Q1 25
$108.5M
$7.0M
Q4 24
$121.1M
$9.8M
Q3 24
$130.5M
$10.5M
Q2 24
$132.2M
$9.0M
Q1 24
$134.5M
$10.6M
Total Assets
ASRT
ASRT
RMCF
RMCF
Q4 25
$267.0M
$20.7M
Q3 25
$319.8M
$22.3M
Q2 25
$273.8M
$20.1M
Q1 25
$286.4M
$21.2M
Q4 24
$284.7M
$21.6M
Q3 24
$276.0M
$21.1M
Q2 24
$279.4M
$19.0M
Q1 24
$282.0M
$20.6M
Debt / Equity
ASRT
ASRT
RMCF
RMCF
Q4 25
Q3 25
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24
0.29×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
ASRT
ASRT
RMCF
RMCF
Operating Cash FlowLast quarter
$-30.0M
$-1.2M
Free Cash FlowOCF − Capex
$-1.3M
FCF MarginFCF / Revenue
-16.9%
Capex IntensityCapex / Revenue
0.5%
Cash ConversionOCF / Net Profit
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
ASRT
ASRT
RMCF
RMCF
Q4 25
$-30.0M
$-1.2M
Q3 25
$-4.8M
$-488.0K
Q2 25
$19.1M
$350.0K
Q1 25
$-12.5M
$1.2M
Q4 24
$11.5M
$-2.1M
Q3 24
$-35.0K
$-3.5M
Q2 24
$7.4M
$-2.2M
Q1 24
$7.5M
$129.0K
Free Cash Flow
ASRT
ASRT
RMCF
RMCF
Q4 25
$-1.3M
Q3 25
$-544.0K
Q2 25
$182.0K
Q1 25
Q4 24
Q3 24
$-4.6M
Q2 24
$-2.6M
Q1 24
$-352.3K
FCF Margin
ASRT
ASRT
RMCF
RMCF
Q4 25
-16.9%
Q3 25
-8.0%
Q2 25
2.9%
Q1 25
Q4 24
Q3 24
-72.6%
Q2 24
-40.2%
Q1 24
-4.9%
Capex Intensity
ASRT
ASRT
RMCF
RMCF
Q4 25
0.5%
Q3 25
0.8%
Q2 25
2.6%
Q1 25
Q4 24
Q3 24
0.0%
17.5%
Q2 24
6.5%
Q1 24
6.6%
Cash Conversion
ASRT
ASRT
RMCF
RMCF
Q4 25
Q3 25
-0.42×
Q2 25
Q1 25
Q4 24
Q3 24
Q2 24
Q1 24

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Revenue Breakdown by Segment

ASRT
ASRT

Products$12.8M95%
Other$719.0K5%

RMCF
RMCF

Manufacturing$5.9M78%
Transferred At Point In Time$1.2M16%
Other$414.0K5%

Related Comparisons